These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2297484)

  • 1. Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
    Cebon JS; Bishop JF; Harvey V; Mason B; Jeal PN
    Br J Cancer; 1990 Jan; 61(1):133-6. PubMed ID: 2297484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
    Parvinen LM; Numminen S
    Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer.
    Carmo-Pereira J; Costa FO; Henriques E; Carvalho V
    Cancer Chemother Pharmacol; 1986; 17(1):87-90. PubMed ID: 3516431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
    Kojima T; Hoshino A; Ohara K; Kamiya O; Nagata K; Ito Y; Kinoshita T; Sugiura I; Yamada M; Sato H
    Cancer Chemother Pharmacol; 1985; 15(3):268-71. PubMed ID: 3902267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Jewell WR; Costanzi JJ; Altman SJ; Minton JP; O'Bryan RM; Osborne CK
    J Clin Oncol; 1993 Sep; 11(9):1710-6. PubMed ID: 8355037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
    Hirshaut Y; Kesselheim H
    Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
    Kolarić K; Roth A; Vukas D; Cervek J
    Cancer Chemother Pharmacol; 1984; 13(2):142-4. PubMed ID: 6380789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
    Tormey DC; Weinberg VE; Leone LA; Glidewell OJ; Perloff M; Kennedy BJ; Cortes E; Silver RT; Weiss RB; Aisner J
    Am J Clin Oncol; 1984 Jun; 7(3):231-9. PubMed ID: 6375344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer.
    Abeloff MD; Beveridge RA; Donehower RC; Fetting JH; Davidson NE; Gordon GG; Waterfield WC; Damron DJ
    J Natl Cancer Inst; 1990 Apr; 82(7):570-4. PubMed ID: 2313733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
    Budd GT; Green S; O'Bryan RM; Martino S; Abeloff MD; Rinehart JJ; Hahn R; Harris J; Tormey D; O'Sullivan J
    J Clin Oncol; 1995 Apr; 13(4):831-9. PubMed ID: 7707108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
    Bishop JF; Dewar J; Toner GC; Smith J; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J; Canetta R
    J Clin Oncol; 1999 Aug; 17(8):2355-64. PubMed ID: 10561297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
    Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
    J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
    Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intensive sequenced adjuvant chemotherapy regimen for breast cancer.
    Bhardwaj S; Holland JF; Norton L
    Cancer Invest; 1993; 11(1):6-9. PubMed ID: 8422597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.